Concord Drugs Limited (BOM:538965)
India · Delayed Price · Currency is INR 62.05
+2.93 (4.96%)
At close: Aug 29, 2025
Concord Drugs Cash Flow Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2016 - 2020 |
|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 | 2016 - 2020 |
Net Income | 3.36 | 4.72 | 9.86 | 15.94 | 32.82 | Upgrade |
Depreciation & Amortization | 14.31 | 15.55 | 16.26 | 17.65 | 13.65 | Upgrade |
Other Operating Activities | 21.65 | 17.95 | 15.16 | 13.84 | 1.61 | Upgrade |
Change in Accounts Receivable | -8.75 | -40.17 | 128.79 | -21.3 | 47.18 | Upgrade |
Change in Inventory | -23.46 | -28.58 | -6.86 | -56.18 | 45.59 | Upgrade |
Change in Accounts Payable | 43.64 | -18.35 | -85.48 | 40.31 | -96.48 | Upgrade |
Change in Income Taxes | -0.18 | -1.58 | -3.24 | 2.01 | 3.52 | Upgrade |
Change in Other Net Operating Assets | -13.35 | 58.37 | -57.85 | -4.52 | -47.89 | Upgrade |
Operating Cash Flow | 37.22 | 7.92 | 16.63 | 7.74 | 0 | Upgrade |
Operating Cash Flow Growth | 369.72% | -52.35% | 114.81% | 4778912.35% | -100.00% | Upgrade |
Capital Expenditures | -23.33 | -10.18 | -8.57 | -24.56 | -36.74 | Upgrade |
Cash Acquisitions | - | - | -14.15 | - | - | Upgrade |
Investment in Securities | 0.14 | 0.09 | 0.06 | - | - | Upgrade |
Other Investing Activities | 0 | -0 | - | 0.12 | 36.74 | Upgrade |
Investing Cash Flow | -23.18 | -10.09 | -22.66 | -24.44 | -0 | Upgrade |
Short-Term Debt Issued | - | 17.23 | - | 47.3 | 36.79 | Upgrade |
Long-Term Debt Issued | 6.79 | - | - | - | - | Upgrade |
Total Debt Issued | 6.79 | 17.23 | - | 47.3 | 36.79 | Upgrade |
Short-Term Debt Repaid | -0.8 | - | -1.56 | - | - | Upgrade |
Long-Term Debt Repaid | - | -12.66 | -0.35 | -12.69 | -2.74 | Upgrade |
Total Debt Repaid | -0.8 | -12.66 | -1.9 | -12.69 | -2.74 | Upgrade |
Net Debt Issued (Repaid) | 5.99 | 4.57 | -1.9 | 34.61 | 34.05 | Upgrade |
Issuance of Common Stock | - | 6.85 | 18.87 | - | - | Upgrade |
Other Financing Activities | -20.27 | -8.58 | -10.72 | -17.83 | -13.31 | Upgrade |
Financing Cash Flow | -14.28 | 2.83 | 6.24 | 16.79 | 20.74 | Upgrade |
Miscellaneous Cash Flow Adjustments | - | - | - | - | -20.5 | Upgrade |
Net Cash Flow | -0.25 | 0.67 | 0.21 | 0.09 | 0.23 | Upgrade |
Free Cash Flow | 13.89 | -2.26 | 8.06 | -16.82 | -36.74 | Upgrade |
Free Cash Flow Margin | 3.07% | -0.50% | 1.55% | -2.85% | -7.14% | Upgrade |
Free Cash Flow Per Share | 1.41 | -0.23 | 0.87 | -1.92 | -4.20 | Upgrade |
Cash Interest Paid | 20.27 | 18.68 | 16.37 | 14.13 | 12.45 | Upgrade |
Cash Income Tax Paid | 2.03 | 2.2 | 3.79 | 6.71 | 0 | Upgrade |
Levered Free Cash Flow | 72.16 | -22.19 | -22.88 | -31.95 | -76.43 | Upgrade |
Unlevered Free Cash Flow | 84.83 | -10.83 | -12.67 | -22.08 | -68.11 | Upgrade |
Change in Working Capital | -2.1 | -30.3 | -24.64 | -39.68 | -48.08 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.